Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Biomarker research has revealed a connection between systemic inflammation and depression.
In a recent survey, more than half the college students with ADHD had at least 1 psychiatric disorder. The recent WHO World Mental Health Survey of college students assessed comorbidities in more than 15,000 college freshmen across 9 countries.
Researchers sought to investigate the association between lower retinal nerve fiber layer thickness, a marker of neurodegeneration, with clinically relevant depressive symptoms and depressive symptoms over time.
People with severe mental illness (SMI) have higher risks for COVID-19 infection, hospitalization, and mortality.
Researchers sought to examine the relationship between depressive symptoms and pain in U.S. veterans 50 years of age or older.
Online single-session interventions (SSIs) appear to offer some benefit for adolescents with depression during the COVID-19 pandemic.
Cognitive behavioral therapy for insomnia (CBT-I) has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder.
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
For patients with severe mental illness, a smartphone intervention is highly usable and acceptable and improves outcomes.